Back to News Research News from 2012

Research News From 2012

    26 December 2012

  1. Integrated Model of Metabolism and Autoimmune Response in beta-Cell Death and Progression to Type 1 Diabetes. Free full text available in HTML and PDF formats.
  2. Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases. Free full text available in HTML and PDF formats.
  3. A Case of Slowly Progressive Type 1 Diabetes with Insulin Independence Maintained for 10 Years with alpha-glucosidase Inhibitor Monotherapy. Free full text available in PDF format.

    19 December 2012

  4. Reversal of diabetes in mice with a bioengineered islet implant incorporating a type I collagen hydrogel and sustained release of vascular endothelial growth factor.
  5. Rotavirus acceleration of murine type 1 diabetes is associated with a T helper 1-dependent specific serum antibody response and virus effects in regional lymph nodes.
  6. Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Free full text available in PDF format. See also Autoimmune Disease: Retraining White Blood Cells.
  7. Does modern high standard life style cause Type 1 diabetes in children?
  8. Primary and secondary prevention of Type 1 diabetes.
  9. Role of immune system modulation in prevention of type 1 diabetes mellitus.

    12 December 2012

  10. Molecular anatomy and number of antigen specific CD8 T cells required to cause type 1 diabetes. Free full text available in HTML and PDF formats.
  11. Pancreas Organ Weight in Individuals With Disease-Associated Autoantibodies at Risk for Type 1 Diabetes. See also UF researchers: Understanding pancreas size may help unlock cause of Type 1 diabetes.

    6 December 2012

  12. An Online Failure Detection Method of the Glucose Sensor-Insulin Pump System: Improved Overnight Safety of Type-1 Diabetic Subjects.
  13. Influenza A viruses grow in human pancreatic cells and cause pancreatitis and diabetes in an animal model. See also Diabetes linked to flu.
  14. Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients.

    28 November 2012

  15. Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes.
  16. Clinical Evaluation of a Personalized Artificial Pancreas.
  17. Enhanced Absorption of Insulin Aspart as the Result of a Dispersed Injection Strategy Tested in a Randomized Trial in Type 1 Diabetic Patients.
  18. Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes.
  19. Lower prediagnostic serum 25-hydroxyvitamin D concentration is associated with higher risk of insulin-requiring diabetes: a nested case–control study. See also Low Vitamin D Level Tied to Type 1 Diabetes.
  20. Metformin Improves Endothelial Function in Type 1 Diabetic Subjects: A Pilot, Placebo-Controlled Randomized Study.
  21. High fructose corn syrup and diabetes prevalence: A global perspective. Free full text available in PDF format. See also Diabetes and Sweetener Link Scrutinized.

    21 November 2012

  22. Islet-Specific CTL Cloned from a Type 1 Diabetes Patient Cause Beta-Cell Destruction after Engraftment into HLA-A2 Transgenic NOD/SCID/IL2RG Null Mice. Free full text available in HTML and PDF formats.
  23. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Free full text available in PDF format.
  24. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. See also Nanoparticle treatment could combat type 1 diabetes.
  25. Reduction in Carotid Intima-Media Thickness After Pancreatic Islet Transplantation in Patients With Type 1 Diabetes.
  26. HLA-A*24 Is an Independent Predictor of 5-Year Progression to Diabetes in Autoantibody-Positive First-Degree Relatives of Type 1 Diabetic Patients.
  27. Family history of Type 1 diabetes affects insulin secretion in patients with 'Type 2' diabetes.
  28. Long-Term Changes in Adiposity and Glycemic Control Are Associated With Past Adenovirus Infection.
  29. Recent incidence of type 1 diabetes mellitus in children 0--14 years in Newfoundland and Labrador, Canada climbs to over 45/100,000: a retrospective time trend study. Free full text available in PDF format.

    14 November 2012

  30. Adult Pancreas Side Population Cells Expand after beta Cell Injury and Are a Source of Insulin-Secreting Cells. See also Pancreas stem cell discovery may lead to new diabetes treatments.
  31. White Matter Microstructural Integrity in Youth With Type 1 Diabetes.
  32. Periodic Extraction of Interstitial Fluid from the Site of Subcutaneous Insulin Infusion for the Measurement of Glucose: A Novel Single-Port Technique for the Treatment of Type 1 Diabetes Patients.
  33. Delayed Small Intestinal Transit in Patients with Long-Standing Type 1 Diabetes Mellitus: Investigation of the Relationships with Clinical Features, Gastric Emptying, Psychological Distress, and Nutritional Parameters.

    7 November 2012

  34. Can we vaccinate against Type 1 diabetes? Free full text available in HTML and PDF formats.
  35. From biomarkers to a clue of biology: a computation-aided perspective of immune gene expression profiles in human type 1 diabetes. Free full text available in HTML and PDF formats.
  36. Novel therapies in the management of type I diabetes mellitus.
  37. Diabetes Death Rates Among Youths Aged <=19 Years — United States, 1968–2009.
  38. High prevalence of vitamin D deficiency among newly diagnosed youth-onset diabetes mellitus in north India. Free full text available in HTML and PDF formats.

    31 October 2012

  39. Real-time assessment of encapsulated neonatal porcine islets prior to clinical xenotransplantation.
  40. Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer.

    24 October 2012

  41. Early Life Socioeconomic Indicators and Risk of Type 1 Diabetes in Children and Young Adults.
  42. Residual beta cell function at diagnosis of Type 1 diabetes in children and adolescents varies with gender and season.
  43. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
  44. The broad clinical phenotype of Type 1 diabetes at presentation.

    18 October 2012

  45. Effect of insulin feedback on closed-loop glucose control: a crossover study.
  46. Feasibility of a bihormonal closed-loop system to control postexercise and postprandial glucose excursions.
  47. Robust fault detection system for insulin pump therapy using continuous glucose monitoring.
  48. Inpatient studies of a Kalman-filter-based predictive pump shutoff algorithm.
  49. Diabetic ketoacidosis at diagnosis: role of family history and class II HLA genotypes.

    10 October 2012

  50. Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase.
  51. Macroporous Three Dimensional PDMS Scaffolds for Extrahepatic Islet Transplantation.
  52. New susceptibility Loci associated with kidney disease in type 1 diabetes. Free full text available in HTML and PDF formats.
  53. Early Childhood Infections and the Risk of Islet Autoimmunity - The Diabetes Autoimmunity Study in the Young (DAISY).
  54. Therapeutic Effects of PPARalpha Agonists on Diabetic Retinopathy in Type 1 Diabetic Models.
  55. Participant characteristics and study features associated with high retention rates in a longitudinal investigation of type 1 diabetes mellitus.

    3 October 2012

  56. Closed-Loop Insulin Therapy Improves Glycemic Control in Children Aged <7 Years.
  57. Extended Family History of Type 1 Diabetes and Phenotype and Genotype of Newly Diagnosed Children.
  58. Pancreatic beta Cell Dedifferentiation as a Mechanism of Diabetic beta Cell Failure.
  59. Pancreas survival in simultaneous pancreas-kidney and pancreas-after-kidney transplantations: A five-year follow-up report.
  60. Rising Incidence of Type 1 Diabetes in Belgrade Children Aged 0-14 in the Period From 1982 to 2005.
  61. Use of continuous glucose monitoring as an outcome measure in clinical trials.
  62. Evaluation of a Novel Continuous Glucose Monitoring-Based Method for Mealtime Insulin Dosing-the iBolus-in Subjects with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Therapy: A Randomized Controlled Trial.
  63. Sleep disturbances and low psychological well-being are associated with an increased risk of autoimmune diabetes in adults. Results from the Nord-Trøndelag Health Study.
  64. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Free full text available in HTML and PDF formats.

    26 September 2012

  65. Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes.
  66. Continuous Glucose Monitoring after Islet Transplantation in Type 1 Diabetes: An Excellent Graft Function (beta-Score Greater Than 7) Is Required to Abrogate Hyperglycemia, Whereas a Minimal Function Is Necessary to Suppress Severe Hypoglycemia (beta-Score Greater Than 3).
  67. The microbiology of human hygiene and its impact on type 1 diabetes.
  68. Prevention of Virus-Induced Type 1 Diabetes with Antibiotic Therapy.
  69. The T1D Exchange Clinic Registry.
  70. Modified release terbutaline (SKP1052) for hypoglycemia prevention: A proof-of-concept study in people with type 1 diabetes mellitus. See also Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes, previously reported (PDF).

    19 September 2012

  71. Stem cells as a tool to improve outcomes of islet transplantation. Free full text available in HTML and PDF formats.
  72. Glucagon secretion and signaling in the development of diabetes. Free full text available in HTML and PDF formats.
  73. Enterovirus-induced gene expression profile is critical for human pancreatic islet destruction.
  74. Teplizumab for Treatment of Type 1 Diabetes Mellitus.

    12 September 2012

  75. On the Etiology of Type 1 Diabetes: A New Animal Model Signifying a Decisive Role for Bacteria Eliciting an Adverse Innate Immunity Response.
  76. White Matter Structural Differences in Young Children With Type 1 Diabetes: A Diffusion Tensor Imaging Study.
  77. Current evidence on the associations of breastfeeding, infant formula, and cow's milk introduction with type 1 diabetes mellitus: a systematic review.
  78. Dysregulated Toll-Like Receptor–Induced Interleukin-1beta and Interleukin-6 Responses in Subjects at Risk for the Development of Type 1 Diabetes.
  79. The BH3-Only Proteins Bim and Puma Cooperate to Impose Deletional Tolerance of Organ-Specific Antigens. See also Immune cell death safeguards against autoimmune disease and Proteins offer protection from type 1 diabetes.

    5 September 2012

  80. Maturation of Human Embryonic Stem Cell–Derived Pancreatic Progenitors Into Functional Islets Capable of Treating Pre-existing Diabetes in Mice. See also UBC scientists reverse diabetes in mice using stem-cell transplants.
  81. Insulin resistance in multiple tissues in patients with type 1 diabetes mellitus on long term continuous subcutaneous insulin infusion therapy.
  82. A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes.
  83. Type I diabetes among children and young adults: the role of country of birth, socioeconomic position and sex.
  84. Factors That Influence Parental Attitudes toward Enrollment in Type 1 Diabetes Trials. Free full text available in HTML and PDF formats.

    30 August 2012

  85. Blood Glucose Control in Type 1 Diabetes With a Bihormonal Bionic Endocrine Pancreas.
  86. A fluorescent responsive hybrid nanogel for closed-loop control of glucose.
  87. Pharmacokinetics and Postprandial Glycemic Excursions following Insulin Lispro Delivered by Intradermal Microneedle or Subcutaneous Infusion.
  88. Islet beta-Cell Mass Preservation and Regeneration in Diabetes Mellitus: Four Factors with Potential Therapeutic Interest. Free full text available in HTML and PDF formats (PDF link in HTML page).
  89. Increasing local blood flow by warming the application site: beneficial effects on postprandial glycemic excursions.
  90. Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes.
  91. Relationship between diabetic retinopathy, microalbuminuria and overt nephropathy, and twenty-year incidence follow-up of a sample of type 1 diabetic patients.
  92. Complications of continuous intraperitoneal insulin infusion with an implantable pump. Free full text available in HTML and PDF formats.

    22 August 2012

  93. Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes. Free full text available in HTML format with link to PDF.
  94. Human embryonic stem cell differentiation into insulin secreting beta cells for diabetes. Free full text available in PDF format.
  95. Three-Dimensional Scaffolds Reduce Islet Amyloid Formation and Enhance Survival and Function of Cultured Human Islets.
  96. The Non-Obese Diabetic (NOD) Mouse as a Model of Human Type 1 Diabetes.
  97. The BB Rat as a Model of Human Type 1 Diabetes.

    8 August 2012

  98. Feasibility Study of Automated Overnight Closed-Loop Glucose Control Under MD-Logic Artificial Pancreas in Patients with Type 1 Diabetes: The DREAM Project.
  99. The Use of an Automated, Portable, Glucose Control System for Overnight Glucose Control in Adolescents and Young Adults With Type 1 Diabetes.
  100. Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes.
  101. Systemic exposure to Pseudomonal bacteria: a potential link between type 1 diabetes and chronic inflammation.
  102. Patient Perspectives on Personalized Glucose Advisory Systems for Type 1 Diabetes Management.
  103. Immunotherapy for Type 1 diabetes: getting beyond a negative first impression.

    1 August 2012

  104. Improvements in the life expectancy of type 1 diabetes; The Pittsburgh Epidemiology of Diabetes Complications Study cohort.
  105. Breast-Feeding and Childhood-Onset Type 1 Diabetes; A pooled analysis of individual participant data from 43 observational studies.
  106. The Effect of Direct Renin Inhibition Alone and in Combination With ACE Inhibition on Endothelial Function, Arterial Stiffness, and Renal Function in Type 1 Diabetes.
  107. History of Cesarean Section Associated with Childhood Onset of T1DM in Newfoundland and Labrador, Canada. Free full text available in HTML and PDF formats.
  108. In vitro generation of functional insulin-producing cells from human bone marrow-derived stem cells, but long-term culture running risk of malignant transformation. Free full text available in HTML and PDF formats.

    25 July 2012

  109. Autologous cord blood harvesting in North Eastern Italy: ethical questions and emerging hopes for curing diabetes and celiac disease. Free full text available in HTML and PDF formats.
  110. Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes.
  111. Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes.
  112. Potential role of non-insulin adjunct therapy in Type 1 diabetes.
  113. Prevention of type 1 diabetes through infection with an intestinal nematode parasite requires IL-10 in the absence of a Th2-type response.
  114. Detection of hypoglycemia associated EEG changes during sleep in type 1 diabetes mellitus.
  115. Plasma C-peptide concentration in women with Type 1 diabetes during early and late pregnancy.
  116. Bayesian analysis of the geographical variation of type 1 diabetes mellitus in under 15 yr olds in northeast Spain, 1991-2009.
  117. The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetes. Free full text available in HTML and PDF formats.

    18 July 2012

  118. Immunoisolation Effect of Polyvinyl Alcohol (PVA) Macroencapsulated Islets in Type 1 Diabetes Therapy.
  119. Relationship between Retinopathy Severity, Visual Impairment and Depression in Persons with Long-term Type 1 Diabetes.

    4 July 2012

  120. Adoptive Transfer of Immunomodulatory M2 Macrophages Prevents Type 1 Diabetes in NOD Mice. See also Researchers prevent mice from developing diabetes.
  121. Long-Term Remission of Diabetes in NOD Mice Is Induced by Nondepleting Anti-CD4 and Anti-CD8 Antibodies.

    27 June 2012

  122. Remission without insulin therapy on gluten-free diet in a 6-year old boy with type 1 diabetes mellitus.
  123. Administration of CD4+CD25highCD127- Regulatory T Cells Preserves beta-Cell Function in Type 1 Diabetes in Children.
  124. Maturation of Human Embryonic Stem Cell–Derived Pancreatic Progenitors into Functional Islets Capable of Treating Pre-existing Diabetes in Mice.

    20 June 2012

  125. Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin. Free full text available in HTML format.
  126. Hyperglycemia Increases Muscle Blood Flow and Alters Endothelial Function in Adolescents with Type 1 Diabetes. Free full text available in HTML and PDF formats.
  127. Use of class I and class II HLA loci for predicting age at onset of type 1 diabetes in multiple populations.
  128. Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control.
  129. A Prototype of a New Noninvasive Device to Detect Nocturnal Hypoglycemia in Adolescents with Type 1 Diabetes-A Pilot Study.

    13 June 2012

  130. Fully Integrated Artificial Pancreas in Type 1 Diabetes - Modular Closed-Loop Glucose Control Maintains Near Normoglycemia.
  131. Fall in C-peptide During First 2 Years From Diagnosis.
  132. Metabolic memory for vascular disease in diabetes.
  133. No evidence of enteroviruses in the intestine of patients with type 1 diabetes.

    6 June 2012

  134. Differential regulation of embryonic and adult beta cell replication. Free full text available in PDF format.
  135. Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes.

    30 May 2012

  136. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. Free full text available in HTML and PDF formats.
  137. Generation of transplantable Beta cells for patient-specific cell therapy. Free full text available in HTML and PDF formats.
  138. Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase.
  139. What is the key environmental trigger in type 1 diabetes - Is it viruses, or wheat gluten, or both?

    23 May 2012

  140. Type 1 diabetes associated and tissue transglutaminase autoantibodies in patients without type 1 diabetes and coeliac disease with confirmed viral infections.
  141. Association between carotid intima-media thickness, buccodental status, and glycemic control in pediatric type 1 diabetes.
  142. Cytokine and Chemokine Production by Human Pancreatic Islets Upon Enterovirus Infection.
  143. The Effect of Type 2 Diabetes Risk Loci on Insulin Requirements in Type 1 Diabetes.
  144. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady state conditions in type 1 diabetes.
  145. Decreased GAD(65) -specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.
  146. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. For more information, visit the JDRF NPOD web site.

    16 May 2012

  147. The Increasing Onset of Type 1 Diabetes in Children.
  148. Emerging Effects of Early Environmental Factors over Genetic Background for Type 1 Diabetes Susceptibility: Evidence from a Nationwide Italian Twin Study.
  149. Incidence of Type 1 Diabetes in Childhood before and after the Reunification of Germany - an Analysis of Epidemiological Data, 1960-2006.
  150. In Vivo Imaging of Endogenous Pancreatic beta-Cell Mass in Healthy and Type 1 Diabetic Subjects Using 18F-Fluoropropyl-Dihydrotetrabenazine and PET.
  151. In vitro and in vivo testing of glucose-responsive insulin-delivery microdevices in diabetic rats.
  152. Mixed Chimerism and Growth Factors Augment beta Cell Regeneration and Reverse Late-Stage Type 1 Diabetes.
  153. Etiopathogenesis of insulin autoimmunity. Free full text available in HTML and PDF formats.

    9 May 2012

  154. Prevention of Type 1A Diabetes. Free full text available in PDF format.
  155. Lack of association of type 2 diabetes susceptibility genotypes and body weight on the development of islet autoimmunity and type 1 diabetes. Free full text available in HTML and PDF formats.
  156. Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. Free full text available in HTML and PDF formats.
  157. Advancing animal models of human type 1 diabetes by engraftment of functional human tissues in immunodeficient mice. Free full text available in HTML and PDF formats.

    2 May 2012

  158. Challenges in diagnosing type 1 diabetes in different populations. Free full text available in HTML and PDF formats.
  159. Clinical performance of a device that applies local heat to the insulin infusion site: a crossover study.
  160. Clinical requirements for closed-loop control systems.
  161. The identifiable virtual patient model: comparison of simulation and clinical closed-loop study results.

    25 April 2012

  162. Xenografted Islet Cell Clusters From INSLEA29Y Transgenic Pigs Rescue Diabetes and Prevent Immune Rejection in Humanized Mice.
  163. Hematopoietic stem cell transplantation for curing children with severe autoimmune diseases: Is this a valid option? (See also hematopoietic stem cell transplantation in Wikipedia.)

    18 April 2012

  164. Potent Induction Immunotherapy Promotes Long-Term Insulin Independence After Islet Transplantation in Type 1 Diabetes.
  165. Human Insulin Secreted From Insulinogenic Xenograft Restores Normoglycemia in Type I Diabetic Mice without Immunosuppression.
  166. An Actor-Critic based controller for glucose regulation in type 1 diabetes.
  167. Birth weight in newborn infants with different diabetes-associated HLA genotypes in three neighboring countries: Finland, Estonia and Russian Karelia.
  168. Infection as a cause of type 1 diabetes?
  169. High-density lipoprotein subspecies between patients with type 1 diabetes and type 2 diabetes without / with intensive insulin therapy.

    11 April 2012

  170. Reversal of Diabetes in Mice with a Bioengineered Islet Implant Incorporating a Type I Collagen Hydrogel and Sustained Release of Vascular Endothelial Growth Factor.
  171. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. See also Engineered Gut Bacteria Reverse Type 1 Diabetes in Experimental Mice.
  172. Antigen targets of type 1 diabetes autoimmunity. Free full text available in HTML and PDF formats.
  173. Pleiotropic action of proinsulin C-peptide.
  174. Enhancing the Accuracy of Subcutaneous Glucose Sensors: A Real-time Deconvolution-based Approach.
  175. The effects of folic acid on markers of endothelial function in patients with type 1 diabetes mellitus.
  176. Differences in recruitment and early retention among ethnic minority participants in a large pediatric cohort: The TEDDY Study.

    4 April 2012

  177. Neighborhood context and incidence of type 1 diabetes: The SEARCH for Diabetes in Youth Study.
  178. Longitudinal trends in use and costs of prescription medication in patients with type 1 diabetes: The impact of renal disease.
  179. Prevalence of gastroparesis-related symptoms in an unselected cohort of patients with Type 1 diabetes.

    28 March 2012

  180. Restoring insulin production for type 1 diabetes.
  181. Improved Preservation of Residual Beta Cell Function by Atorvastatin in Patients with Recent Onset Type 1 Diabetes and High CRP Levels (DIATOR Trial). Free full text available in HTML and PDF via link.
  182. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk.
  183. Improving cellular function and immune protection via layer-by-layer nanocoating of pancreatic islet beta-cell spheroids cocultured with mesenchymal stem cells.
  184. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes.
  185. Gastric Autoimmunity in Children and Adolescents with Type 1 Diabetes: A Prospective Study.

    21 March 2012

  186. Maternal Enterovirus Infection as a Risk Factor for Type 1 Diabetes in the Exposed Offspring.
  187. Induction Therapy With Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants. See also Collaborative Study from the Diabetes Research Institute Federation and The Cure Alliance Shows that Stem Cells Can Replace Powerful Anti-Rejection Drug to Prevent Rejection and Improve Outcome in Transplant Recipients.
  188. Autologous Hematopoietic Stem Cell Transplantation Modulates Immunocompetent Cells and Improves beta-Cell Function in Chinese Patients with New Onset of Type 1 Diabetes.
  189. Glucose-stimulated insulin secretion of various mesenchymal stem cells after insulin-producing cell differentiation.
  190. Urinary markers of renal inflammation in adolescents with Type 1 diabetes mellitus and normoalbuminuria.
  191. Costs of paediatric diabetes care in Germany: current situation and comparison with the year 2000.
  192. Distinguishing type 2 diabetes from type 1 diabetes in african american and Hispanic american pediatric patients. Free full text available in HTML and PDF formats.

    14 March 2012

  193. Removal of Bovine Insulin From Cow's Milk Formula and Early Initiation of Beta-Cell Autoimmunity in the FINDIA Pilot Study.
  194. Effects of Diet Soda on Gut Hormones in Youths With Diabetes.
  195. Whole-Blood Tissue Factor Procoagulant Activity Is Elevated in Type 1 Diabetes and Effects of Hyperglycemia and Hyperinsulinemia.
  196. Association of Basal hyperglucagonemia with impaired glucagon counterregulation in type 1 diabetes. Free full text available in HTML and PDF formats.
  197. Autoantibodies and High-Risk HLA Susceptibility Markers in First-Degree Relatives of Brazilian Patients with Type 1 Diabetes Mellitus: A Progression to Disease Based Study.
  198. Generation of functional insulin-producing cells in the gut by Foxo1 ablation. See also Gut Cells Turned To Insulin Factories - New Type l Diabetes Treatment.

    7 March 2012

  199. Closed-loop insulin delivery: towards improved diabetes care. Free full text available in HTML format.
  200. The interplay of autoimmunity and insulin resistance in type 1 diabetes. Free full text available in HTML format.
  201. Increasing Incidence and Age at Diagnosis among Children with Type 1 Diabetes Mellitus over a 20-Year Period in Auckland (New Zealand).
  202. Glycotoxin and Autoantibodies Are Additive Environmentally Determined Predictors of Type 1 Diabetes; A Twin and Population Study.
  203. Immunology in the clinic review series; focus on type 1 diabetes and viruses: the enterovirus link to type 1 diabetes: critical review of human studies.

    29 February 2012

  204. Reversal of Diabetes Through Gene Therapy of Diabetic Rats by Hepatic Insulin Expression via Lentiviral Transduction.
  205. The Accuracy Benefit of Multiple Amperometric Glucose Sensors in People With Type 1 Diabetes.
  206. Preexisting Autoantibodies Predict Efficacy of Oral Insulin To Cure Autoimmune Diabetes in Combination With Anti-CD3.
  207. Effect of the PTPN22 and INS Risk Genotypes on the Progression to Clinical Type 1 Diabetes After the Initiation of beta-cell Autoimmunity.
  208. Historical data enhances safety supervision system performance in T1DM insulin therapy risk management.
  209. Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism.
  210. Arterial Stiffness Is Increased in Patients With Type 1 Diabetes Without Cardiovascular Disease; A potential role of low-grade inflammation.

    22 February 2012

  211. Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay. See also Study finds some insulin production in long-term type 1 diabetes and Insulin production may persist for decades after onset of type 1 diabetes.
  212. Does severe hypoglycaemia influence microvascular complications in Type 1 diabetes? An analysis of the Diabetes Control and Complications Trial database.

    15 February 2012

  213. Genetics of type 1 diabetes. Free full text available in HTML and PDF formats.
  214. Virus infections in type 1 diabetes. Free full text available in HTML and PDF formats.
  215. CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Free full text available in HTML and PDF formats.
  216. Could the social environment trigger the induction of diabetes related autoantibodies in young children?
  217. Infant and Toddler Type 1 Diabetes: Complications after 20 years’ duration.
  218. Reversal of diabetes by beta-TC3 cells encapsulated in alginate beads generated by emulsion and internal gelation.
  219. Hypoglycemia, but not Glucose Variability, Relates to Vascular Function in Children with Type 1 Diabetes.
  220. Hyperfiltration in type 1 diabetes: does it exist and does it matter for nephropathy?
  221. The branching pattern of villous capillaries and structural changes of placental terminal villi in type 1 diabetes mellitus.
  222. Long-Term (5 Years) Efficacy and Safety of Pancreas Transplantation Alone in Type 1 Diabetic Patients.
  223. 8 February 2012

  224. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
  225. Reversal of Type 1 Diabetes in Mice by Brown Adipose Tissue Transplant.
  226. Type 1 Diabetes Is Associated With Enterovirus Infection in Gut Mucosa.
  227. Is the origin of type 1 diabetes in the gut?
  228. Rising Incidence of Type 1 Diabetes Is Associated With Altered Immunophenotype at Diagnosis.
  229. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes.
  230. Interbirth Interval Is Associated With Childhood Type 1 Diabetes Risk.
  231. East Africans in Sweden Have a High Risk for Type 1 Diabetes.
  232. Age-Related Loss of Brain Volume and T2 Relaxation Time in Youth With Type 1 Diabetes.

    1 February 2012

  233. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Free full text available in HTML and PDF formats.
  234. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
  235. Diabetic retinopathy in the SEARCH for Diabetes in Youth Cohort: a pilot study.
  236. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
  237. Serum 25-hydroxyvitamin D level during early pregnancy and type 1 diabetes risk in the offspring.
  238. Proinsulin C-peptide interferes with insulin fibril formation.

    25 January 2012

  239. Development of a fully automated closed loop artificial pancreas control system with dual pump delivery of insulin and glucagon.
  240. Islet autoantibodies and residual beta cell function in type 1 diabetes children followed for 3-6 years.
  241. Advanced Glycation End Products as Environmental Risk Factors for the Development of Type 1 Diabetes.
  242. A novel strategy for long-term implantable artificial pancreas.

    18 January 2012

  243. Safe Glycemic Management during Closed-Loop Treatment of Type 1 Diabetes: The Role of Glucagon, Use of Multiple Sensors, and Compensation for Stress Hyperglycemia.
  244. Closed-loop glucose control: psychological and behavioral considerations.
  245. Continuous glucose monitoring considerations for the development of a closed-loop artificial pancreas system.
  246. A controlled study of the effectiveness of an adaptive closed-loop algorithm to minimize corticosteroid-induced stress hyperglycemia in type 1 diabetes.
  247. Meta-analysis of overnight closed-loop randomized studies in children and adults with type 1 diabetes: the cambridge cohort.
  248. Neighborhood level risk factors for type 1 diabetes in youth: the SEARCH case-control study.
  249. Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.
  250. Left ventricular filling patterns and its relation to left ventricular untwist in patients with type 1 diabetes and normal ejection fraction.
  251. The Timing of Dialysis and Kidney Transplantation in Type 1 Diabetes.

    11 January 2012

  252. Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells. Free full text available in PDF format. See also Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes and Type 1 Diabetes Reversed With Stem Cells From Cord Blood.
  253. Characterization of a Novel Functional Protein in the Pancreatic Islet: Islet Homeostasis Protein Regulation of Glucagon Synthesis in alpha Cells. See also Researchers Discover Protein that May Represent New Target for Treating Type 1 Diabetes.
  254. Promoting long-term survival of insulin-producing cell grafts that differentiate from adipose tissue-derived stem cells to cure type 1 diabetes. Free full text available in HTML and PDF formats.
  255. 25-Hydroxyvitamin D Concentrations and In Vivo Insulin Sensitivity and beta-Cell Function Relative to Insulin Sensitivity in Black and White Youth.
  256. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes.
  257. Blue Flash ERG PhNR Changes Associated with Poor Long-Term Glycemic Control in Adolescents with Type 1 Diabetes.

    4 January 2012

  258. Towards an artificial pancreas at home.
  259. Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps.
  260. Regulated and Reversible Induction of Adult Human beta-Cell Replication.
  261. Latent Autoimmune Diabetes of Adults Is Phenotypically Similar to Type 1 Diabetes in a Minority Population.

[ Current Research News | News from 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 ]

  Back to News Return to the Top of This Page

Last Updated: Thursday January 01, 2015 15:29:01
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.